Symptom Burden As Primary Driver for Therapy in Patients with Myelofibrosis: An Analysis By MPN International Quality of Life Study GroupRobyn M. Scherber, Ruben A. Mesa, Dolores Hernández‐Maraver et al.|Blood|2016Cited by 5
PRIMARY MYELOFIBROSIS, POST-ET AND POST-PV MYELOFIBROSIS HAVE DISTINCT CLINICAL PROFILES AND SYMPTOMATIC BURDENS : AN ANALYSIS BY THE MPN QUALITY OF LIFE INTERNATIONAL STUDY GROUP (MPN-QOL ISG)Holly L. Geyer, Ruben A. Mesa, Heidi Kosiorek et al.|Haematologica|2015Cited by 2
Gender Differences and MPN Symptom Burden : An Analysis by the MPN Quality of Life International Study Group (MPN-QOL ISG)Holly L. Geyer, Reyes López de Mesa, Robyn M. Emanuel et al.|Unknown|2014Cited by 2
Impact Of Splenomegaly On Mpn Symptoms And Association With Clinical Features : An Analysis By The Mpn Quality Of Life International Study GroupHolly L. Geyer, Ruben A. Mesa, R. Scherber et al.|Haematologica|2016Cited by 1
Consideration of Symptom Burden Based Treatment in PV and ET Patients: An Analysis By MPN International Quality of Life Study GroupRobyn M. Scherber, Ruben A. Mesa, Holly L. Geyer et al.|Blood|2016Cited by 0